Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial - Anchalee Avihingsanon; Michael D. Hughes; Robert Salata; Catherine Godfrey; Sharlaa Badal-Faesen; Lerato Mohapi; E et al (My University, 2023)